Venture
Apnimed, Inc.
Latest Form D 2026-03-27- CIK 1745648
- State MA
- Pharmaceuticals
- 9 Form D offerings since 2018-07-06
- Total sold
- $284M
- across 9 offerings
- Rounds
- 9
- Form D offerings since 2018-07-06
- Latest round
- $25M
- 2026-03-27 · 021-578027
- Investors
- 2
- on the latest round
Connected
named in its Form D filingsRound timeline
amount sold · by first filed2026-03-27 · $25M
- 2018-07-06$25.6M021-316175
- 2020-04-07$15M021-364430
- 2021-03-25$25M021-393539
- 2022-05-10$62.5M021-445175
- 2022-12-23$79.7M021-468579
- 2023-11-08$0021-496807
- 2025-04-24$16.5M021-544389
- 2025-09-24$35M021-558476
- 2026-03-27$25M021-578027
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($79.7M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-578027 | First filed2026-03-27 | Latest2026-03-27 | Sought$25M | Sold$25M | Investors2 | Exemptions506(b) |
| 021-558476 | First filed2025-09-24 | Latest2025-12-08 | Sought$35M | Sold$35M | Investors7 | Exemptions506(b) |
| 021-544389 | First filed2025-04-24 | Latest2025-04-24 | Sought$16.5M | Sold$16.5M | Investors3 | Exemptions506(b) |
| 021-496807 | First filed2023-11-08 | Latest2023-11-08 | Sought$37.5M | Sold$0 | Investors1 | Exemptions506(b) |
| 021-468579 | First filed2022-12-23 | Latest2022-12-23 | Sought$79.7M | Sold$79.7M | Investors6 | Exemptions506(b) |
| 021-445175 | First filed2022-05-10 | Latest2022-11-01 | Sought$62.5M | Sold$62.5M | Investors14 | Exemptions506(b) |
| 021-393539 | First filed2021-03-25 | Latest2021-03-25 | Sought$25M | Sold$25M | Investors3 | Exemptions506(b) |
| 021-364430 | First filed2020-04-07 | Latest2020-04-07 | Sought$15M | Sold$15M | Investors1 | Exemptions506(b) |
| 021-316175 | First filed2018-07-06 | Latest2019-08-07 | Sought$25.6M | Sold$25.6M | Investors12 | Exemptions506(b) |
Who backs Apnimed, Inc., inferred from co-filings, and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2026-03-27
| Name | Relationship |
|---|---|
| Lawrence G. Miller | RelationshipExecutive Officer, Director |
| Barry Wohl | RelationshipExecutive Officer |
| Dennis Molnar | RelationshipExecutive Officer |
| Joseph C. Avellone | RelationshipDirector |
| Francois Beaubien | RelationshipDirector |
| Isaac Cheng | RelationshipDirector |
| Chris C. Dimitropoulos | RelationshipDirector |
| Paul Fonteyne | RelationshipDirector |
| Kevin C. Lind | RelationshipDirector |
| Gary Sender | RelationshipDirector |
| Ramzi Benamar | RelationshipExecutive Officer |
Facts
As its latest Form D states them
- Industry
- Pharmaceuticals
- State
- Massachusetts (MA)
- Exemptions
- Rule 506(b)
- First filed
- 2018-07-06
- Latest filing
- 2026-03-27
Who backs Apnimed, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗